Recent Updates
Recently added Catalysts
EBS Positive Sentiment

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility GAITHERSBURG, Md.

Key Takeaway: Emergent BioSolutions Inc. has announced the closing of a $100 million asset-based revolving loan facility, with Wells Fargo Bank as the administrative agent. This credit agreement is part of Emergent's multi-year transformation plan and has a maturity date of September 30, 2029. The company reported a cash balance of approximately $150 million and indicates that this facility will provide additional liquidity for its strategic goals. This move follows a recent announcement of refinancing efforts, enhancing Emergent's overall financial strength.
Price reaction · baseline $8.47 (2024-10-01 close) · hit after-hours · clean, no other EBS news in the window
day 0 close
+8.5%
day 1
+5.5%
day 3 · peak
+8.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Emergent has successfully closed a new ABL credit facility with favorable terms.
  • The new facility supports the company's multi-year transformation plan.
  • Emergent's cash balance and undrawn access to funds strengthen its financial position.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+70%
120-day peak, hindsight
Typical move
8%
average across 2 past catalysts
Lead asset
FLU-IGIV
Phase 2 · Influenza A H3N2

Full Press Release Details

Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility
GAITHERSBURG, Md., Oct 2, 2024 Emergent BioSolutions Inc. (NYSE: EBS) announced today that it entered into a new credit agreement on September 30,
2024 providing for an asset-based revolving loan facility (ABL) with the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent. The credit agreement provides for revolving loan commitments in an aggregate
principal amount up to $100 million (availability is based on a borrowing base set forth therein) with a fixed maturity date of September 30, 2029, subject to early maturity triggers based on the maturity of its other material
indebtedness. The new credit facility brings additional liquidity to support Emergent s multi-year transformation plan. As of September 30, 2024, Emergent had a cash balance of approximately $150 million and undrawn access to
$100 million under the ABL.
We are pleased to have successfully closed on our new ABL credit facility with favorable terms and an extended
maturity, which is further evidence of Emergent s strengthened balance sheet and financial position, said Joe Papa, president and CEO, Emergent. As we continue to execute on our multi-year transformation plan, we have made
significant progress on our stabilization efforts to date, all while staying the course on strategic goals, to deliver long-term value and sustainable growth in the future.
This agreement follows Emergent s September 3, 2024 announcement that it successfully refinanced its debt and closed a new credit facility
agreement with Oak Hill Advisors for a term loan of up to $250 million.
About Emergent BioSolutions
At Emergent, our mission is to protect and enhance life. For 25 years, we ve been at work defending people from things we hope will never happen so
we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of
Safe Harbor Statement
This press release includes
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by
using words like anticipate, believe, continue, could, estimate, expect, forecast, future, goal, intend, may,
plan, position, possible, potential, predict, project, should, target, will, would, and similar expressions or variations
thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that
is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ
materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do
not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.
There are a number of important factors that could cause the company s actual results to differ
materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange
Commission, when evaluating our forward-looking statements.
Executive Vice President, CFO

Frequently Asked Questions

What is the amount of Emergent BioSolutions' new loan facility?

Emergent BioSolutions secured a $100 million asset-backed loan facility.

Who is the administrative agent for the new credit agreement?

Wells Fargo Bank, National Association, serves as the administrative agent.

What is the fixed maturity date of the new loan facility?

The fixed maturity date for the loan facility is September 30, 2029.

What financial goal is supported by this new credit facility?

The facility supports Emergent's multi-year transformation plan for liquidity.

What was Emergent's cash balance as of September 30, 2024?

As of that date, Emergent had a cash balance of approximately $150 million.

Last updated: Oct 2, 2024